Zai Lab Ltd
ZLAB · XNASCIK 1704292fmd_173EPQ6ZRV9N07PYAZRA1C6CXWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 35 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 13 | 49 | 144 | 215 | 267 | 399 | 460 |
| Cost of revenue | – | – | 0 | 4 | 17 | 52 | 74 | 96 | 147 | 191 |
| Gross profit | – | – | 0 | 9 | 32 | 92 | 141 | 171 | 252 | 270 |
| Research and development | 32 | 39 | 120 | 142 | 223 | 573 | 286 | 266 | 235 | 221 |
| Selling, general and administrative | 6 | 12 | 22 | 70 | 111 | 219 | 259 | 282 | 299 | 278 |
| Operating income | (39) | (51) | (142) | (203) | (302) | (700) | (404) | (367) | (282) | (229) |
| Interest expense | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 |
| Interest and investment income | 0 | 1 | 3 | 8 | 5 | 2 | 15 | 40 | 37 | 33 |
| Other non-operating income (expense) | – | 1 | 0 | 1 | 7 | (10) | 3 | 7 | 5 | 4 |
| Income before taxes | (38) | (50) | (139) | (195) | (269) | (704) | (443) | (335) | (257) | (178) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (3) |
| Net income from continuing operations | – | (50) | (139) | (195) | (269) | (704) | (443) | (335) | (257) | (176) |
| Net income | (38) | (50) | (139) | (195) | (269) | (704) | (443) | (335) | (257) | (176) |
| Net income to common shareholders | (38) | (50) | (139) | (195) | (269) | (704) | (443) | (335) | (257) | (176) |